Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task ForceKlaus Beiske, Katherine K. Matthay|British Journal of Cancer|2009Cited by 134
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial resultsKelly C. Goldsmith, Yaël P. Mossé, Fariba Goodarzian et al.|Nature Medicine|2023Cited by 125
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory NeuroblastomaSteven G. DuBois, Araz Marachelian, Yaël P. Mossé et al.|Clinical Cancer Research|2018Cited by 88
Paracrine Signaling Through MYCN Enhances Tumor-Vascular Interactions in NeuroblastomaYvan H. Chanthery, William A. Weiss, W. Clay Gustafson et al.|Science Translational Medicine|2012Cited by 86
Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trialNavin Pinto, Julie R. Park, Steven G. DuBois et al.|Pediatric Blood & Cancer|2018Cited by 39